TSH Biopharm Corporation Limited (TPEX:8432)
Taiwan · Delayed Price · Currency is TWD 48.80
0.00 (0.00%)
Jul 30, 2026, 1:30 PM CST
TSH Biopharm Corporation Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,874 | 2,246 | 2,354 | 1,931 | 1,826 | 1,709 | |
Market Cap Growth | 0.62% | -4.57% | 21.87% | 5.78% | 6.85% | -24.45% |
Enterprise Value | 1,100 | 1,610 | 1,785 | 1,230 | 1,111 | 926 |
Last Close Price | 48.80 | 55.62 | 55.85 | 44.90 | 40.97 | 37.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.71 | 16.13 | 20.81 | 31.16 | 29.50 | 36.27 |
Forward PE | - | 18.74 | 18.74 | 18.74 | 18.74 | 18.74 |
PS Ratio | 1.40 | 1.68 | 2.11 | 2.38 | 2.46 | 4.13 |
PB Ratio | 1.07 | 1.31 | 1.45 | 1.53 | 1.51 | 1.58 |
P/TBV Ratio | 1.58 | 1.95 | 2.13 | 1.83 | 1.77 | 1.58 |
P/FCF Ratio | 6.78 | 16.64 | 12.93 | 67.79 | 59.62 | 25.01 |
P/OCF Ratio | 6.70 | 16.10 | 12.81 | 57.02 | 53.15 | 24.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.82 | 1.21 | 1.60 | 1.52 | 1.50 | 2.24 |
EV/EBITDA Ratio | 4.32 | 6.96 | 9.64 | 15.84 | 14.02 | 15.21 |
EV/EBIT Ratio | 4.82 | 7.37 | 10.51 | 19.33 | 16.83 | 16.65 |
EV/FCF Ratio | 3.98 | 11.93 | 9.81 | 43.18 | 36.28 | 13.55 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 | 0.00 |
Debt / EBITDA Ratio | 0.07 | 0.08 | 0.10 | 0.09 | 0.73 | 0.07 |
Debt / FCF Ratio | 0.06 | 0.14 | 0.11 | 0.26 | 2.06 | 0.07 |
Net Debt / Equity Ratio | -0.60 | -0.53 | -0.54 | -0.60 | -0.62 | -0.67 |
Net Debt / EBITDA Ratio | -4.35 | -3.95 | -4.74 | -9.85 | -9.49 | -11.97 |
Net Debt / FCF Ratio | -3.81 | -6.77 | -4.82 | -26.84 | -24.58 | -10.67 |
Asset Turnover | 0.69 | 0.71 | 0.69 | 0.57 | 0.57 | 0.35 |
Inventory Turnover | 4.03 | 3.95 | 3.62 | 3.64 | 3.89 | 2.20 |
Quick Ratio | 5.74 | 5.49 | 5.32 | 7.35 | 4.96 | 9.72 |
Current Ratio | 6.45 | 6.27 | 6.25 | 8.34 | 5.56 | 10.72 |
Return on Equity (ROE) | 11.44% | 11.24% | 9.29% | 5.24% | 5.76% | 4.26% |
Return on Assets (ROA) | 7.40% | 7.20% | 6.55% | 2.81% | 3.17% | 2.90% |
Return on Invested Capital (ROIC) | 24.07% | 22.54% | 21.06% | 11.30% | 13.19% | 11.14% |
Return on Capital Employed (ROCE) | 13.00% | 12.70% | 10.40% | 5.00% | 5.40% | 5.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.88% | 6.20% | 4.81% | 3.21% | 3.39% | 2.76% |
FCF Yield | 14.75% | 6.01% | 7.73% | 1.47% | 1.68% | 4.00% |
Dividend Yield | 5.22% | 4.69% | 3.80% | 2.85% | 3.91% | 4.05% |
Payout Ratio | 55.17% | 58.45% | 43.46% | 99.11% | 93.06% | 146.72% |
Buyback Yield / Dilution | -0.03% | -0.05% | -0.04% | 0.05% | -0.05% | -0.01% |
Total Shareholder Return | 5.16% | 4.64% | 3.76% | 2.90% | 3.86% | 4.05% |